SMS Pharmaceuticals logo

SMS Pharmaceuticals MD, chairman, board of directors and AGM

NSE: SMSPHARMABSE: 532815Pharmaceuticals & BiotechnologySmall Cap

Last close ₹414.60down ₹14.05 (3.28%)BSE ₹414.70

Share price at the NSE close on 23 Oct 2026. Previous close ₹428.65.

52-week range of traded prices to 23 Oct 2026
₹270.10Low, 24 Nov 2025₹494.45High, 22 Sep 2026
Market cap
₹3,883 Cr920th largest listed
P/E
37.8
P/B
4.9
Dividend yield
0.10%
ROE
14.4%
ROCE
11.5%
Debt to equity
0.46
Volume, NSE
4,58,39343.4% delivered

SMS Pharmaceuticals board of directors

At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • Chairperson and managing directorRamesh Babu Potluri

8 directors4 independent2 executive2 non-executive

  • Ramesh Babu Potluri · Chairperson and managing directorExecutive · joined Aug 1990 · reappointed Oct 2021 · 0 months as independent · 1 listed board
  • Shravan KudaravalliIndependent · joined Sep 2018 · reappointed May 2023 · 40 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
  • Sarvepalli SrinivasIndependent · joined Aug 2019 · reappointed Aug 2024 · 25 months as independent · 1 listed board · 1 as independent · 1 committee seat
  • Vamsi Krishna PotluriExecutive · joined Jun 2020 · reappointed Jul 2025 · 0 months as independent · 1 listed board · 1 committee seat
  • Trilok PotluriNon-executive · joined Aug 2024 · 0 months as independent · 1 listed board · 1 committee seat
  • Sunkara Venkata Satya Shiva PrasadNon-executive · joined Aug 2024 · 0 months as independent · 2 listed boards · 1 as independent · 2 committee seats, 1 as chair
  • Suresh Kumar GangavarapuIndependent · joined Aug 2024 · 25 months as independent · 1 listed board · 1 as independent · 1 committee seat
  • Shanti Sree BolleniIndependent · joined Aug 2024 · 25 months as independent · 5 listed boards · 5 as independent · 9 committee seats, 1 as chair

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 31 Jul 20268 of 8 present4 independent · 69 days in between
    • 22 May 20268 of 8 present4 independent

  • Audit Committee

    Chair Shravan Kudaravalli

    Suresh Kumar Gangavarapu, Vamsi Krishna Potluri, Shanti Sree Bolleni

    • 31 Jul 20264 of 4 present3 independent · 70 days in between
    • 21 May 20264 of 4 present3 independent

  • Nomination and remuneration committee

    Chair Shanti Sree Bolleni

    Suresh Kumar Gangavarapu, Sunkara Venkata Satya Shiva Prasad

    • 31 Jul 20263 of 3 present2 independent

  • Stakeholders Relationship Committee

    Chair Sunkara Venkata Satya Shiva Prasad

    Trilok Potluri, Sarvepalli Srinivas, Shanti Sree Bolleni

    No meeting listed in the filing.

  • Risk Management Committee

    Chair Ramesh Babu Potluri

    Vamsi Krishna Potluri, Shravan Kudaravalli

    • 29 Aug 20263 of 3 present1 independent · 28 days in between

  • Corporate Social Responsibility Committee

    Chair Ramesh Babu Potluri

    Shravan Kudaravalli, Sarvepalli Srinivas

    No meeting listed in the filing.

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Jun 2026.

  • M/s.Suryanarayana & Suresh, Chartered AccountantsPeer-review certificate valid to Jul 2026

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

SMS Pharmaceuticals AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.SMS Pharmaceuticals dividend history

Annual general meeting, 29 Sep 2026

36,232 shareholders on the register on 22 Sep 2026; present: 7 promoters and 69 others; votes counted by C. SUDHIR BABU / CSB ASSOCIATES, PRATICING COMPANY SECRETARIES.The company's voting result (opens in a new tab)

  1. Adoption of Financial Statements for the Financial Year 2025-26
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.70%

    Turnout: all 81.15% · promoters 100.00% · institutions 8.69% · other public 42.33%

  2. Declaration of Dividend on the Equity Shares of the Company for the Financial Year 2025-26
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.70%

    Turnout: all 81.15% · promoters 100.00% · institutions 8.69% · other public 42.33%

  3. Re-appointment of Dr. Sunkara Venkata Satya Shiva Prasad (DIN: 10404277) who retires by rotation, and being eligible, offers himself for re-appointment
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.78% · other public 0.71%

    Turnout: all 81.14% · promoters 100.00% · institutions 8.69% · other public 42.27%

  4. Approval of Material Related Party Transactions with M/s. VKT Pharma Private Limited
    OrdinaryPromoters have an interest in it
    99.30% for0.70% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.70%

    Turnout: all 13.07% · promoters 0.00% · institutions 8.69% · other public 42.27%

  5. Approval For Remuneration Payable to the Cost Auditors for the Financial Year 2026-27
    Ordinary
    99.89% for0.11% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.70%

    Turnout: all 81.15% · promoters 100.00% · institutions 8.69% · other public 42.33%

  6. Approval for Re-appointment of Mr. Ramesh Babu Potluri (DIN: 00166381) as Chairman and Managing Director of the Company and fixation of remuneration
    SpecialPromoters have an interest in it
    99.43% for0.57% against

    Against: promoters 0.00% · institutions 66.95% · other public 0.00%

    Turnout: all 13.07% · promoters 0.00% · institutions 8.69% · other public 42.27%

  7. Approval to provide loan to SMS Peptides Private Limited, Subsidiary Company
    SpecialPromoters have an interest in it
    99.30% for0.70% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.70%

    Turnout: all 13.07% · promoters 0.00% · institutions 8.69% · other public 42.27%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 29 Sep 2025, 7 resolutions

35,604 shareholders on the register on 22 Sep 2025; present: 7 promoters and 52 others; votes counted by C. SUDHIR BABU / CSB ASSOCIATES, PRATICING COMPANY SECRETARIES.The company's voting result (opens in a new tab)

  1. Adoption of Financial Statements
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 80.50% · promoters 100.00% · institutions 90.16% · other public 36.86%

  2. Declaration of dividend on Equity shares for the financial year 2024-2025
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 80.50% · promoters 100.00% · institutions 90.16% · other public 36.86%

  3. Re-appointment of Mr. Trilok Potluri (DIN: 07634613), who retires by rotation, at this Annual General Meeting and being eligible, offers himself for re-appointment
    OrdinaryPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 13.93% · promoters 0.00% · institutions 90.16% · other public 35.87%

  4. Approval of material related party transaction(s) with VKT Pharma Private Limited
    OrdinaryPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 13.93% · promoters 0.00% · institutions 90.16% · other public 35.87%

  5. Approval for remuneration payable to the Cost Auditors for the Financial Year 2025-2026
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 80.50% · promoters 100.00% · institutions 90.16% · other public 36.86%

  6. Approval for Appointment of Secretarial Auditors of the Company
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 80.50% · promoters 100.00% · institutions 90.16% · other public 36.86%

  7. Approval for re-appointment of Mr. Vamsi Krishna Potluri (DIN: 06956498) as Executive Director and fix the remuneration
    SpecialPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.05% · other public 0.00%

    Turnout: all 13.93% · promoters 0.00% · institutions 90.16% · other public 35.87%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 30 Sep 2024, 10 resolutions

Present: 9 promoters and 56 others.The company's voting result (opens in a new tab)

  1. Adoption of Financial Statements
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 81.11% · promoters 100.00% · institutions 83.71% · other public 42.94%

  2. DECLARATION OF DIVIDEND ON EQUITY SHARES FORnTHE FINANCIAL YEAR 2023-24
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 81.11% · promoters 100.00% · institutions 83.71% · other public 42.94%

  3. RE-APPOINTMENT OF MR. VAMSI KRISHNA POTLURIn(DIN: 06956498) WHO RETIRES BY ROTATION,nAND BEING ELIGIBLE, AND OFFERS HIMSELF FORnREAPPOINTMENT
    OrdinaryPromoters have an interest in it
    99.59% for0.41% against

    Against: promoters 0.00% · institutions 2.54% · other public 0.01%

    Turnout: all 16.42% · promoters 0.00% · institutions 83.71% · other public 42.88%

  4. APPROVAL OF MATERIAL RELATED PARTYnTRANSACTIONS WITH VKT PHARMA PRIVATE LIMITEDn(VKT PHARMA).
    OrdinaryPromoters have an interest in it
    99.59% for0.41% against

    Against: promoters 0.00% · institutions 2.54% · other public 0.01%

    Turnout: all 16.44% · promoters 0.00% · institutions 83.71% · other public 42.94%

  5. APPROVAL OF REMUNERATION PAYABLE TO THEnCOST AUDITORS FOR THE FINANCIAL YEAR 2024-n2025
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 81.11% · promoters 100.00% · institutions 83.71% · other public 42.94%

  6. APPOINTMENT OF MR. TRILOK POTLURI (DIN:n07634613) AS A NON- EXECUTIVE NON INDEPENDENTnDIRECTOR
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.04% · other public 0.01%

    Turnout: all 16.44% · promoters 0.00% · institutions 83.71% · other public 42.94%

  7. APPOINTMENT OF DR. SUNKARA VENKATA SATYAnSHIVA PRASAD (DIN: 10404277) AS A NON- EXECUTIVEnNON INDEPENDENT DIRECTOR
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.04% · other public 0.01%

    Turnout: all 16.23% · promoters 0.00% · institutions 83.71% · other public 42.29%

  8. APPOINTMENT OF DR. SURESH KUMAR GANGAVARAPUn(DIN: 00183128) AS AN INDEPENDENT DIRECTOR
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 81.09% · promoters 100.00% · institutions 83.71% · other public 42.86%

  9. APPOINTMENT OF MRS. SHANTI SREE BOLLENI (DIN:n07092258) AS AN INDEPENDENT DIRECTOR
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 81.11% · promoters 100.00% · institutions 83.71% · other public 42.94%

  10. RE-APPOINTMENT OF MR. SARVEPALLI SRINIVASn(DIN: 02292051) AS AN INDEPENDENT DIRECTOR
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 81.11% · promoters 100.00% · institutions 83.71% · other public 42.94%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Extraordinary general meeting, 6 Mar 2024, 1 resolution

Present: 8 promoters and 65 others.The company's voting result (opens in a new tab)

  1. ISSUE OF CONVERTIBLE WARRANTS ON A PREFERENTIAL BASIS TO PROMOTERS/ PROMOTERS GROUP OF THE COMPANY
    SpecialPromoters have an interest in it
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 15.72% · promoters 0.00% · institutions 0.00% · other public 44.14%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 30 Sep 2023, 7 resolutions

Present: 9 promoters and 57 others.The company's voting result (opens in a new tab)

  1. Adoption of Financial Statements
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 79.26% · promoters 100.00% · institutions 1.29% · other public 42.58%

  2. Declaration of Dividend on equity shares for the Financial Year 2022-23
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 79.26% · promoters 100.00% · institutions 1.29% · other public 42.58%

  3. Re-appointment of Mr. Ramesh Babu Potluri (DIN: 00166381) who retires by rotation, and being eligible, and offers himself for reappointment
    OrdinaryPromoters have an interest in it
    99.98% for0.02% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.02%

    Turnout: all 14.95% · promoters 0.00% · institutions 1.29% · other public 42.58%

  4. Approval to provide security in the form of pledge of shares held by the company in VKT Pharma Private Limited (VKT Pharma) in connection with Non-Convertible Debentures (NCDs) to be issued by VKT Pharma, as specified under Section 185 of the Companies Act, 2013.MoreLess
    SpecialPromoters have an interest in it
    99.67% for0.33% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.33%

    Turnout: all 14.95% · promoters 0.00% · institutions 1.29% · other public 42.58%

  5. Approval of Material Related Party Transaction(s) to provide pledge of shares held by the company in VKT Pharma Private Limited (VKT Pharma) in connection with Non-Convertible Debentures (NCDs) to be issued by VKT Pharma.MoreLess
    OrdinaryPromoters have an interest in it
    99.67% for0.33% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.33%

    Turnout: all 14.95% · promoters 0.00% · institutions 1.29% · other public 42.58%

  6. Approval of material related party transaction(s) for sale and purchase of material with VKT Pharma Private Limited.
    OrdinaryPromoters have an interest in it
    99.62% for0.38% against

    Against: promoters 0.00% · institutions 95.99% · other public 0.33%

    Turnout: all 14.95% · promoters 0.00% · institutions 1.29% · other public 42.58%

  7. Ratification of remuneration payable to the Cost Auditor for the Financial Year 2023-2024
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 79.26% · promoters 100.00% · institutions 1.29% · other public 42.58%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 10 Aug 2023, 1 resolution

The company's voting result (opens in a new tab)

  1. Re-appointment of Mr. Shravan Kudaravalli (DIN: 06905851) as an Independent Director of the Company, for a further period of 5 (Five) consecutive years
    Special
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.58%

    Turnout: all 69.35% · promoters 100.00% · institutions 0.04% · other public 14.37%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 30 Sep 2022, 7 resolutions

Present: 5 promoters and 67 others.The company's voting result (opens in a new tab)

  1. Adoption of Financial Statements
    Ordinary
    98.82% for1.18% against

    Against: promoters 1.41% · institutions 0.00% · other public 0.01%

    Turnout: all 77.25% · promoters 100.00% · institutions 0.05% · other public 37.11%

  2. Declaration of Dividend on Equity Shares for the Financial Year 2021-22.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 77.25% · promoters 100.00% · institutions 0.05% · other public 37.11%

  3. Re-appointment of Mr. Vamsi Krishna Potluri (DIN: 06956498) who retires by rotation, and being eligible, and offers himself for reappointment.
    OrdinaryPromoters have an interest in it
    99.98% for0.02% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.02%

    Turnout: all 13.07% · promoters 0.00% · institutions 0.05% · other public 37.11%

  4. Re-appointment of M/s. Suryanarayana & Suresh, Chartered Accountants as Statutory Auditors of the Company.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 77.25% · promoters 100.00% · institutions 0.05% · other public 37.11%

  5. Ratify / Approve the Related Party Contracts/ Arrangements/ Transactions of the Company for the Financial Year 2021-2022
    OrdinaryPromoters have an interest in it
    99.98% for0.02% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.02%

    Turnout: all 13.07% · promoters 0.00% · institutions 0.05% · other public 37.11%

  6. Approval for the Material Related Party Transactions of the Company.
    OrdinaryPromoters have an interest in it
    99.75% for0.25% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.25%

    Turnout: all 13.07% · promoters 0.00% · institutions 0.05% · other public 37.11%

  7. Ratification of Remuneration payable to the Cost Auditor for the Financial Year 2022-23.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 77.25% · promoters 100.00% · institutions 0.05% · other public 37.11%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 29 Mar 2022, 4 resolutions

The company's voting result (opens in a new tab)

  1. Approval for Related Party Transactions
    OrdinaryPromoters have an interest in it
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.06%

    Turnout: all 10.65% · promoters 0.00% · institutions 0.00% · other public 33.21%

  2. Approval for the payment of remuneration as per terms currently in force tonMr. Ramesh Babu Potluri, in his capacity as Chairman & Managing Directornof the Company in excess of limits prescribed under of Regulation 17(6)(e)(i) of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015.nMoreLess
    SpecialPromoters have an interest in it
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.06%

    Turnout: all 10.65% · promoters 0.00% · institutions 0.00% · other public 33.21%

  3. Approval for the payment of remuneration as per terms currently in force to Mr. Vamsi Krishna Potluri, in his capacity as Whole- Time Director of the Company in excess of limits prescribed under of Regulation 17(6)(e)(i) of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015.MoreLess
    SpecialPromoters have an interest in it
    99.93% for0.07% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.07%

    Turnout: all 10.65% · promoters 0.00% · institutions 0.00% · other public 33.21%

  4. Approval for increase in aggregate annual remuneration payable to Managing Director and Whole-Time Director (s) pursuant to regulation 17(6)(e)(ii) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.MoreLess
    SpecialPromoters have an interest in it
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.06%

    Turnout: all 10.65% · promoters 0.00% · institutions 0.00% · other public 33.21%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.

Mutual fund votes, meeting of 29 Sep 2025, 3 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • Adoption of Financial Statements
    3 for0 against
  • Declaration of dividend on Equity shares for the financial year 2024-2025
    3 for0 against
  • Re-appointment of Mr. Trilok Potluri (DIN: 07634613), who retires by rotation, at this Annual General Meeting and being eligible, offers himself for re-appointment
    3 for0 against
  • Approval of material related party transaction(s) with VKT Pharma Private Limited
    3 for0 against
  • Approval for remuneration payable to the Cost Auditors for the Financial Year 2025-2026
    3 for0 against
  • Approval for Appointment of Secretarial Auditors of the Company
    2 for0 against
  • Approval for re-appointment of Mr. Vamsi Krishna Potluri (DIN: 06956498) as Executive Director and fix the remuneration
    Against Bandhan Mutual Fund
    • Bandhan Mutual Fund"Vamsi Krishna Potluri, 36, is part of the promoter family (son of Ramesh Babu Potluri, Chairperson and MD) and serves as Executive Director of SMS Pharmaceuticals Limited (SMS Pharma). He attended all four board meetings held in FY25. We raise concern over his membership of the Audit Committee; we believe it must only comprise Independent Directors to avoid potential conflict of interest. His FY25 pay aggregated Rs. 51.8 mn. Both Vamsi Krishna Potluri and Ramesh Babu Potluri drew similar levels of pay and thus the pay to promoter Executive Directors aggregated Rs. 103.7 mn in FY25, which is high at 11.2% of the consolidated FY25 PBT and is not commensurate with the company’s size. The company proposes to reappoint him at a fixed pay of Rs. 18.0 mn per annum, excluding allowances, perquisites, other benefits, and remuneration linked to net profits (commission). The company has not provided any guidance on the commission, nor has it capped it in absolute terms. The company should have disclosed performance metrics that determine his variable pay. He received ~4.8% of standalone PBT as commission in FY25. Assuming a similar range of commission (based on TTM results), we estimate his FY26 pay at Rs. 66.4 mn, which is high for the company’s size. He also serves as the Managing Director of VKT Pharma Private Limited, an associate company with common promoters, in which SMS Pharma has 34.8% equity. Given his two executive positions, the company must clarify if the NRC has satisfied itself that he can devote sufficient time to his responsibilities at SMS Pharma. Further, we also raise concern that he is eligible for reimbursement of medical expenses. We believe such expenses are personal in nature and should be borne by directors themselves. The company may instead consider acquiring health insurance, since contributions are capped, or otherwise capping such reimbursements in absolute terms. We do not support the resolution."
    2 for1 against
1 proposal not matched to one resolution
  • 6. Approval for Appointment of SecretarialAuditors of the Company
    1 for0 against

Mutual fund votes, meeting of 30 Sep 2024, 3 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • Adoption of Financial Statements
    3 for0 against
  • DECLARATION OF DIVIDEND ON EQUITY SHARES FORnTHE FINANCIAL YEAR 2023-24
    2 for0 against
  • RE-APPOINTMENT OF MR. VAMSI KRISHNA POTLURIn(DIN: 06956498) WHO RETIRES BY ROTATION,nAND BEING ELIGIBLE, AND OFFERS HIMSELF FORnREAPPOINTMENT
    2 for0 against
  • APPROVAL OF MATERIAL RELATED PARTYnTRANSACTIONS WITH VKT PHARMA PRIVATE LIMITEDn(VKT PHARMA).
    2 for0 against
  • APPOINTMENT OF MR. TRILOK POTLURI (DIN:n07634613) AS A NON- EXECUTIVE NON INDEPENDENTnDIRECTOR
    2 for0 against
  • APPOINTMENT OF DR. SUNKARA VENKATA SATYAnSHIVA PRASAD (DIN: 10404277) AS A NON- EXECUTIVEnNON INDEPENDENT DIRECTOR
    2 for0 against
  • APPOINTMENT OF DR. SURESH KUMAR GANGAVARAPUn(DIN: 00183128) AS AN INDEPENDENT DIRECTOR
    2 for0 against
  • APPOINTMENT OF MRS. SHANTI SREE BOLLENI (DIN:n07092258) AS AN INDEPENDENT DIRECTOR
    2 for0 against
  • RE-APPOINTMENT OF MR. SARVEPALLI SRINIVASn(DIN: 02292051) AS AN INDEPENDENT DIRECTOR
    2 for0 against
1 proposal not matched to one resolution
  • Ratification of remuneration of Rs. 1,00,000/- and taxes as applicable plus out of packet expenses payable to M/s. Harshitha Annapragada and Co., Cost Accountants having Firm Registration No. 006031 appointed by the Board of Directors of the Company to conduct the Cost Audit for the Financial Year 2024 - 2025MoreLess
    2 for0 against
4 earlier meetings

Mutual fund votes, meeting of 6 Mar 2024, 1 fund house

  • ISSUE OF CONVERTIBLE WARRANTS ON A PREFERENTIAL BASIS TO PROMOTERS/ PROMOTERS GROUP OF THE COMPANY
    1 for0 against

Mutual fund votes, meeting of 30 Sep 2023, 1 fund house

  • Adoption of Financial Statements
    1 for0 against
  • Declaration of Dividend on equity shares for the Financial Year 2022-23
    1 for0 against
  • Re-appointment of Mr. Ramesh Babu Potluri (DIN: 00166381) who retires by rotation, and being eligible, and offers himself for reappointment
    1 for0 against
  • Approval to provide security in the form of pledge of shares held by the company in VKT Pharma Private Limited (VKT Pharma) in connection with Non-Convertible Debentures (NCDs) to be issued by VKT Pharma, as specified under Section 185 of the Companies Act, 2013.MoreLess
    1 for0 against
  • Approval of Material Related Party Transaction(s) to provide pledge of shares held by the company in VKT Pharma Private Limited (VKT Pharma) in connection with Non-Convertible Debentures (NCDs) to be issued by VKT Pharma.MoreLess
    1 for0 against
  • Approval of material related party transaction(s) for sale and purchase of material with VKT Pharma Private Limited.
    1 for0 against
  • Ratification of remuneration payable to the Cost Auditor for the Financial Year 2023-2024
    1 for0 against

Mutual fund votes, meeting of 10 Aug 2023, 1 fund house

  • Re-appointment of Mr. Shravan Kudaravalli (DIN: 06905851) as an Independent Director of the Company, for a further period of 5 (Five) consecutive years
    1 for0 against

Mutual fund votes, meeting of 30 Sep 2022, 1 fund house

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • Adoption of Financial Statements
    1 for0 against
  • Declaration of Dividend on Equity Shares for the Financial Year 2021-22.
    1 for0 against
  • Re-appointment of Mr. Vamsi Krishna Potluri (DIN: 06956498) who retires by rotation, and being eligible, and offers himself for reappointment.
    1 for0 against
  • Re-appointment of M/s. Suryanarayana & Suresh, Chartered Accountants as Statutory Auditors of the Company.
    1 for0 against
  • Approval for the Material Related Party Transactions of the Company.
    1 for0 against
  • Ratification of Remuneration payable to the Cost Auditor for the Financial Year 2022-23.
    1 for0 against
1 proposal not matched to one resolution
  • Approval/Ratification of related party transactions for purchase and sale of products/by-products/material at arm’s length price with VKT Pharma Private Limited and SMS Lifesciences India Limited, Eshwar Coal Movers and Pixalot Labs Private Limited.MoreLess
    1 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Tax disputes

Reported in the filing for the quarter to Sep 2026.

  • Tax disputeFaceless Assessment Unit, Income Tax DepartmentSince 23 Mar 2025
    Appeal preferred by the Company are pending before Commissioner of Income Tax (Appeals).
    At the filing before: The Company received an assessment order dated 22nd March, 2025 under Section 144 read with Section 144B of the Income Tax Act, 1961 for AY 2023-24, raising a demand of Rs. 45.63 Crores (including interest) along with penalty proceedings. The Company has filed an appeal before the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre and a grievance before the High-Pitched Assessment Committee. Stay petitions have also been filed before the Assessing Officer and the Principal Commissioner of Income Tax, Hyderabad. The Company has duly responded to all notices, including penalty-related communications, and submitted requisite information within prescribed timelines.MoreLess
  • Tax disputeFaceless Assessment Unit, Income Tax DepartmentSince 31 Mar 2026
    Appeal preferred by the Company are pending before Commissioner of Income Tax (Appeals).
    At the filing before: The Company has received an assessment order under Section 147 read with section 144B of the Income Tax Act, 1961 for Assessment Year 2018-19, by addition of income and disallowance of deduction u/s 35 of the Act., and Income Tax demand notice dated 30th March 2026, received on 31st March 2026. under Section 156 of the Income Tax Act, 1961, raised a demand of Rs.7.19 crores for the Assessment Year 2018-19. Further, penalty proceedings u/s 270A is initiated separately for under reporting of income. The Company has filed Rectification application under Section 154 was filed before DCIT, Hyderabad. Pursuant to the rectification order the tax demand was reduced from Rs.7.19 crore to Rs.40.28 lakh which was allowed by the DCIT. The company also filed an Appeal before CIT(A), NFAC against the above order and the same has been admitted. The Company has duly responded to all notices, including penalty-related communications, and submitted requisite information within prescribed timelines. The Income Tax Department has adjusted the AY 2025-26 refund against the outstanding demand for the above demand i.e. AY 2018-19MoreLess

In the company's own words, from its latest governance filing.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
Yes
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
Yes
There was a cyber security incident in the quarter
No

The company's own answers in its filing.

How money raised was used

Reported for the quarter to Mar 2026. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.

RaisedAmount raisedForSet asideSpentSpent elsewhere
Preferential IssuesMar 2024, checked by CARE Ratings Limited114.30Capital Expenditure: Expansion of production capacities in phased manner and installation of additional utility equipments as well as recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&D by setting up new production blocks.62.8763.40No
Preferential IssuesMar 2024, checked by CARE Ratings Limited114.30Working Capital: Expanding the production capacities, backward integration of KSM, which led to an increased requirement of Working Capital, operational expenditure and other related expenses.40.0040.00No
Preferential IssuesMar 2024, checked by CARE Ratings Limited114.30General Corporate Purposes: which includes, inter alia, meeting ongoing general corporate exigencies and contingencies, expenses of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable laws.11.4310.89No
₹ crore. Checked by is the agency appointed to monitor how the money is used. The reason and the comments are the company's, its audit committee's and its auditors' own words.